{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,7]],"date-time":"2026-08-07T16:18:29Z","timestamp":1786119509971,"version":"build-2736575974"},"reference-count":57,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"3","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2011,5]]},"DOI":"10.1097\/mjt.0b013e3181cea0cd","type":"journal-article","created":{"date-parts":[[2010,3,24]],"date-time":"2010-03-24T04:15:25Z","timestamp":1269404125000},"page":"e55-e66","source":"Crossref","is-referenced-by-count":5,"title":["Optimization of Anticoagulation with Warfarin for Stroke Prevention: Pharmacogenetic Considerations"],"prefix":"10.1097","volume":"18","author":[{"given":"Ales","family":"Tomek","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vaclav","family":"Matoska","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christian","family":"Eisert","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Victor L","family":"Serebruany","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-13-20210202","doi-asserted-by":"crossref","first-page":"1647","DOI":"10.1161\/STROKEAHA.107.189063","article-title":"Update to the AHA\/ASA recommendations for the prevention of stroke in patients with stroke and transient ischemic attack.","volume":"39","author":"Adams","year":"2008","journal-title":"Stroke"},{"key":"R2-13-20210202","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1159\/000131083","article-title":"Guidelines for management of ischaemic stroke and transient ischaemic attack 2008.","volume":"25","year":"2008","journal-title":"Cerebrovasc Dis"},{"key":"R3-13-20210202","first-page":"CD002005","article-title":"Anticoagulation for cerebral sinus thrombosis.","volume":"4","author":"Stam","year":"2002","journal-title":"Cochrane Database Syst Rev"},{"key":"R4-13-20210202","doi-asserted-by":"crossref","first-page":"857","DOI":"10.7326\/0003-4819-146-12-200706190-00007","article-title":"Meta-analysis: antithrombotic therapy to prevent stroke in patients who have nonvalvular atrial fibrillation.","volume":"146","author":"Hart","year":"2007","journal-title":"Ann Intern Med"},{"key":"R5-13-20210202","doi-asserted-by":"crossref","first-page":"1457","DOI":"10.1016\/S0140-6736(99)04407-4","article-title":"Treatment and secondary prevention of stroke: evidence, costs, and effects on individuals and populations.","volume":"354","author":"Hankey","year":"1999","journal-title":"Lancet"},{"key":"R6-13-20210202","doi-asserted-by":"crossref","first-page":"753","DOI":"10.1056\/NEJMoa0809329","article-title":"Estimation of the warfarin dose with clinical and pharmacogenetic data.","volume":"360","author":"International Warfarin Pharmacogenetics Consortium, Klein","year":"2009","journal-title":"N Engl J Med"},{"key":"R7-13-20210202","doi-asserted-by":"crossref","first-page":"784","DOI":"10.1182\/blood-2008-04-149070","article-title":"The largest prospective warfarin-treated cohort supports genetic forecasting.","volume":"113","author":"Wadelius","year":"2009","journal-title":"Blood"},{"key":"R8-13-20210202","doi-asserted-by":"crossref","first-page":"2285","DOI":"10.1056\/NEJMoa044503","article-title":"Effect of VKORC1 haplotypes on transcriptional regulation and warfarin dose.","volume":"352","author":"Rieder","year":"2005","journal-title":"N Engl J Med"},{"key":"R9-13-20210202","doi-asserted-by":"crossref","first-page":"722","DOI":"10.1038\/clpt.2008.166","article-title":"Pharmacogenetics of warfarin: development of a dosing algorithm for Brazilian patients.","volume":"84","author":"Perini","year":"2008","journal-title":"Clin Pharmacol Ther"},{"key":"R10-13-20210202","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1007\/s00439-006-0260-8","article-title":"Association of warfarin dose with genes involved in its action and metabolism.","volume":"121","author":"Wadelius","year":"2007","journal-title":"Hum Genet"},{"key":"R11-13-20210202","doi-asserted-by":"crossref","first-page":"1337","DOI":"10.1124\/mol.109.054833","article-title":"CYP4F2 is a vitamin K1 oxidase: an explanation for altered warfarin dose in carriers of the V433M variant.","volume":"75","author":"McDonald","year":"2009","journal-title":"Mol Pharmacol"},{"key":"R12-13-20210202","doi-asserted-by":"crossref","first-page":"e1000433","DOI":"10.1371\/journal.pgen.1000433","article-title":"A genome-wide association study confirms VKORC1, CYP2C9, and CYP4F2 as principal genetic determinants of warfarin dose.","volume":"5","author":"Takeuchi","year":"2009","journal-title":"PLoS Genet"},{"key":"R13-13-20210202","doi-asserted-by":"crossref","first-page":"261","DOI":"10.2217\/14622416.10.2.261","article-title":"CYP4F2 genetic variant (rs2108622) significantly contributes to warfarin dosing variability in the Italian population.","volume":"10","author":"Borgiani","year":"2009","journal-title":"Pharmacogenomics"},{"key":"R14-13-20210202","doi-asserted-by":"crossref","first-page":"2227","DOI":"10.1111\/j.1538-7836.2007.02744.x","article-title":"-Glutamyl carboxylase (GGCX) tagSNPs have limited utility for predicting warfarin maintenance dose.","volume":"5","author":"Rieder","year":"2007","journal-title":"J Thromb Hemost"},{"key":"R15-13-20210202","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1038\/sj.tpj.6500445","article-title":"Apolipoprotein E genotype and warfarin dosing among Caucasians and African Americans.","volume":"8","author":"Kimmel","year":"2008","journal-title":"Pharmacogenomics J"},{"key":"R16-13-20210202","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1016\/j.cca.2008.07.005","article-title":"Genetic factors contribute to patient-specific warfarin dose for Han Chinese.","volume":"396","author":"Wang","year":"2008","journal-title":"Clin Chim Acta"},{"key":"R17-13-20210202","doi-asserted-by":"crossref","first-page":"1690","DOI":"10.1001\/jama.287.13.1690","article-title":"Association between CYP2C9 genetic variants and anticoagulation-related outcomes during warfarin therapy.","volume":"287","author":"Higashi","year":"2002","journal-title":"JAMA"},{"key":"R18-13-20210202","doi-asserted-by":"crossref","first-page":"1123","DOI":"10.1160\/TH04-02-0083","article-title":"Warfarin dosing and cytochrome P450 2C9 polymorphisms.","volume":"91","author":"Joffe","year":"2004","journal-title":"Thromb Haemost"},{"key":"R19-13-20210202","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1160\/TH07-09-0552","article-title":"An analysis of the relative effects of VKORC1 and CYP2C9 variants on anticoagulation related outcomes in warfarin patients.","volume":"100","author":"Meckley","year":"2008","journal-title":"Thromb Haemost"},{"key":"R20-13-20210202","doi-asserted-by":"crossref","first-page":"717","DOI":"10.1016\/S0140-6736(98)04474-2","article-title":"Association of polymorphisms in the cytochrome P450 CYP2C9 with warfarin dose requirement and risk of bleeding complications.","volume":"353","author":"Aithal","year":"1999","journal-title":"Lancet"},{"key":"R21-13-20210202","doi-asserted-by":"crossref","first-page":"775","DOI":"10.1055\/s-0037-1614114","article-title":"Genetic modulation of oral anticoagulation with warfarin.","volume":"84","author":"Margaglione","year":"2000","journal-title":"Thromb Haemost"},{"key":"R22-13-20210202","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1097\/01.GIM.0000153664.65759.CF","article-title":"References Cyp2c9 gene variants, drug dose, and bleeding risk in warfarin-treated patients: a HuGEnet systematic review and meta-analysis.","volume":"7","author":"Sanderson","year":"2005","journal-title":"Genet Med"},{"key":"R23-13-20210202","doi-asserted-by":"crossref","first-page":"2329","DOI":"10.1182\/blood-2005-03-1108","article-title":"The impact of CYP2C9 and VKORC1 genetic polymorphism and patient characteristics upon warfarin dose requirements: proposal for a new dosing regimen.","volume":"106","author":"Sconce","year":"2005","journal-title":"Blood"},{"key":"R24-13-20210202","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1016\/j.clpt.2005.01.019","article-title":"CYP2C9 haplotype structure in European American warfarin patients and association with clinical outcomes.","volume":"77","author":"Veenstra","year":"2005","journal-title":"Clin Pharmacol Ther"},{"key":"R25-13-20210202","doi-asserted-by":"crossref","first-page":"262","DOI":"10.1038\/sj.tpj.6500313","article-title":"Common VKORC1 and GGCX polymorphisms associated with warfarin dose.","volume":"5","author":"Wadelius","year":"2005","journal-title":"Pharmacogenomics J"},{"key":"R26-13-20210202","doi-asserted-by":"crossref","first-page":"999","DOI":"10.1056\/NEJMoa0708078","article-title":"Genetic determinants of response to warfarin during initial anticoagulation.","volume":"358","author":"Schwarz","year":"2008","journal-title":"N Engl J Med"},{"key":"R27-13-20210202","doi-asserted-by":"crossref","first-page":"312","DOI":"10.1038\/sj.clpt.6100290","article-title":"Influence of CYP2C9 and VKORC1 1173C\/T genotype on the risk of hemorrhagic complications in African-American and European-American patients on warfarin.","volume":"83","author":"Limdi","year":"2008","journal-title":"Clin Pharmacol Ther"},{"key":"R28-13-20210202","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1038\/nature02214","article-title":"Mutations in VKORC1 cause warfarin resistance and multiple coagulation factor deficiency type 2.","volume":"427","author":"Rost","year":"2004","journal-title":"Nature"},{"key":"R29-13-20210202","doi-asserted-by":"crossref","first-page":"570","DOI":"10.1160\/TH07-07-0454","article-title":"Current pharmacogenetic developments in oral anticoagulation therapy: the influence of variant VKORC1 and CYP2C9 alleles.","volume":"98","author":"Oldenburg","year":"2007","journal-title":"Thromb Haemost"},{"key":"R30-13-20210202","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1023\/A:1025052827305","article-title":"Warfarin dose adjustments based on CYP2C9 genetic polymorphisms.","volume":"14","author":"Linder","year":"2002","journal-title":"J Thromb Thrombolysis"},{"key":"R31-13-20210202","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1016\/j.cll.2008.09.001","article-title":"Pharmacogenetic testing for warfarin sensitivity.","volume":"28","author":"Lyon","year":"2008","journal-title":"Clin Lab Med"},{"key":"R32-13-20210202","doi-asserted-by":"crossref","first-page":"S160","DOI":"10.1378\/chest.08-0670","article-title":"Pharmacology and management of the vitamin K Antagonists: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines, 8th ed.","volume":"133","author":"Ansell","year":"2008","journal-title":"Chest"},{"key":"R33-13-20210202","first-page":"62","article-title":"Randomized assessment of a warfarin nomogram for initial oral anticoagulation after venous thromboembolic disease.","volume":"28","author":"Kovacs","year":"1998","journal-title":"Haemostasis"},{"key":"R34-13-20210202","doi-asserted-by":"crossref","first-page":"1268","DOI":"10.1136\/bmj.288.6426.1268","article-title":"Flexible induction dose regimen for warfarin and prediction of maintenance dose.","volume":"288","author":"Fennerty","year":"1984","journal-title":"BMJ"},{"key":"R35-13-20210202","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1055\/s-0037-1613446","article-title":"A randomized trial of initial warfarin dosing based on simple clinical criteria.","volume":"89","author":"Shine","year":"2003","journal-title":"Thromb Haemost"},{"key":"R36-13-20210202","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1007\/s11239-006-9030-7","article-title":"Genotypes of the cytochrome p450 isoform, CYP2C9, and the vitamin K epoxide reductase complex subunit 1 conjointly determine stable warfarin dose: a prospective study.","volume":"22","author":"Carlquist","year":"2006","journal-title":"J Thromb Thrombolysis"},{"key":"R37-13-20210202","doi-asserted-by":"crossref","first-page":"2563","DOI":"10.1161\/CIRCULATIONAHA.107.737312","article-title":"Randomized trial of genotype-guided versus standard warfarin dosing in patients initiating oral anticoagulation.","volume":"116","author":"Anderson","year":"2007","journal-title":"Circulation"},{"key":"R38-13-20210202","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1160\/TH03-06-0379","article-title":"Use of pharmacogenetics and clinical factors to predict the maintenance dose of warfarin.","volume":"91","author":"Gage","year":"2004","journal-title":"Thromb Haemost"},{"key":"R39-13-20210202","doi-asserted-by":"crossref","first-page":"326","DOI":"10.1038\/clpt.2008.10","article-title":"Use of pharmacogenetic and clinical factors to predict the therapeutic dose of warfarin.","volume":"84","author":"Gage","year":"2008","journal-title":"Clin Pharmacol Ther"},{"key":"R40-13-20210202","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1097\/01.fpc.0000114760.08559.dc","article-title":"Relative impact of covariates in prescribing warfarin according to CYP2C9 genotype.","volume":"14","author":"Hillman","year":"2004","journal-title":"Pharmacogenetics"},{"key":"R41-13-20210202","doi-asserted-by":"crossref","first-page":"346","DOI":"10.1016\/j.clpt.2006.06.009","article-title":"A warfarin-dosing model in Asians that uses single-nucleotide polymorphisms in vitamin K epoxide reductase complex and cytochrome P450 2C9.","volume":"80","author":"Tham","year":"2006","journal-title":"Clin Pharmacol Ther"},{"key":"R42-13-20210202","doi-asserted-by":"crossref","first-page":"1135","DOI":"10.1007\/s00228-007-0381-6","article-title":"Contribution of age, body weight, and CYP2C9 and VKORC1 genotype to the anticoagulant response to warfarin: proposal for a new dosing regimen in Chinese patients.","volume":"63","author":"Miao","year":"2007","journal-title":"Eur J Clin Pharmacol"},{"key":"R43-13-20210202","doi-asserted-by":"crossref","first-page":"332","DOI":"10.1038\/clpt.2008.101","article-title":"Dosing algorithms to predict warfarin maintenance dose in Caucasians and African Americans.","volume":"84","author":"Schelleman","year":"2008","journal-title":"Clin Pharmacol Ther"},{"key":"R44-13-20210202","doi-asserted-by":"crossref","first-page":"226","DOI":"10.1097\/FPC.0b013e328326e0c7","article-title":"Validation of VKORC1 and CYP2C9 genotypes on interindividual warfarin maintenance dose: a prospective study in Chinese patients.","volume":"19","author":"Huang","year":"2009","journal-title":"Pharmacogenet Genomics"},{"key":"R45-13-20210202","doi-asserted-by":"crossref","first-page":"1511","DOI":"10.1182\/blood-2007-01-069609","article-title":"Genetic-based dosing in orthopedic patients beginning warfarin therapy.","volume":"110","author":"Millican","year":"2007","journal-title":"Blood"},{"key":"R46-13-20210202","doi-asserted-by":"crossref","first-page":"740","DOI":"10.1038\/sj.clpt.6100434","article-title":"Combination of phenotype assessments and CYP2C9-VKORC1 polymorphisms in the determination of warfarin dose requirements in heavily medicated patients.","volume":"83","author":"Michaud","year":"2008","journal-title":"Clin Pharmacol Ther"},{"key":"R47-13-20210202","doi-asserted-by":"crossref","first-page":"137","DOI":"10.3121\/cmr.3.3.137","article-title":"A prospective, randomized pilot trial of model-based warfarin dose initiation using CYP2C9 genotype and clinical data.","volume":"3","author":"Hillman","year":"2005","journal-title":"Clin Med Res"},{"key":"R48-13-20210202","doi-asserted-by":"crossref","first-page":"460","DOI":"10.1038\/sj.clpt.6100316","article-title":"CYP2C9 genotype-guided warfarin prescribing enhances the efficacy and safety of anticoagulation: a prospective randomized controlled study.","volume":"83","author":"Caraco","year":"2008","journal-title":"Clin Pharmacol Ther"},{"key":"R49-13-20210202","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1016\/j.thromres.2006.09.007","article-title":"Genotypes of vitamin K epoxide reductase, -glutamyl carboxylase, and cytochrome P450 2C9 as determinants of daily warfarin dose in Japanese patients.","volume":"120","author":"Kimura","year":"2007","journal-title":"Thromb Res"},{"key":"R50-13-20210202","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1067\/mcp.2001.119812","article-title":"Impaired cognitive function and compliance with antihypertensive drugs in elderly: the Rotterdam study.","volume":"70","author":"Salas","year":"2001","journal-title":"Clin Pharmacol Ther"},{"key":"R51-13-20210202","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1007\/s12529-009-9052-6","article-title":"Patient attitudinal behavioral factors associated with warfarin non-adherence at outpatient anticoagulation clinics.","volume":"17","author":"Cruess","year":"2010","journal-title":"Int J Behav Med"},{"key":"R52-13-20210202","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1186\/1471-2377-8-25","article-title":"Medication persistence rates and factors associated with persistence in patients following stroke: a cohort study.","volume":"8","author":"Lummis","year":"2008","journal-title":"BMC Neurol"},{"key":"R53-13-20210202","doi-asserted-by":"crossref","first-page":"432","DOI":"10.1016\/S0002-9343(02)01253-6","article-title":"A population-based study of mortality among patients with atrial fibrillation or flutter.","volume":"113","author":"Vidaillet","year":"2002","journal-title":"Am J Med"},{"key":"R54-13-20210202","doi-asserted-by":"crossref","first-page":"1324","DOI":"10.1136\/bmj.318.7194.1324","article-title":"Implementing evidence based medicine in general practice: audit and qualitative study of antithrombotic treatment for atrial fibrillation.","volume":"318","author":"Howitt","year":"1999","journal-title":"BMJ"},{"key":"R55-13-20210202","first-page":"493","article-title":"Managed care in the genomics era: assessing the cost effectiveness of genetic tests.","volume":"9","author":"Higashi","year":"2003","journal-title":"Am J Manag Care"},{"key":"R56-13-20210202","doi-asserted-by":"crossref","first-page":"73","DOI":"10.7326\/0003-4819-150-2-200901200-00005","article-title":"Cost-effectiveness of using pharmacogenetic information in warfarin dosing for patients with nonvalvular atrial fibrillation.","volume":"150","author":"Eckman","year":"2009","journal-title":"Ann Intern Med"},{"key":"R57-13-20210202","doi-asserted-by":"crossref","first-page":"540","DOI":"10.1038\/clpt.2009.104","article-title":"Potential clinical and economic outcomes of CYP2C9 and VKORC1 genotype-guided dosing in patients starting warfarin therapy.","volume":"86","author":"You","year":"2009","journal-title":"Clin Pharmacol Ther"}],"container-title":["American Journal of Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/10.1097\/MJT.0b013e3181cea0cd","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,6]],"date-time":"2026-08-06T18:19:37Z","timestamp":1786040377000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/00045391-201105000-00013"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011,5]]},"references-count":57,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2011]]}},"URL":"https:\/\/doi.org\/10.1097\/mjt.0b013e3181cea0cd","relation":{},"ISSN":["1075-2765"],"issn-type":[{"value":"1075-2765","type":"print"}],"subject":[],"published":{"date-parts":[[2011,5]]}}}